NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 14596-37-3
Drug Levels and Effects
Summary of Use during Lactation
Information in this record refers to the use of phosphorus P 32 as a therapeutic agent. No information is available on the use of phosphorus P 32 during breastfeeding. Use of phosphate P 32 as a skin patch to treat skin cancers poses no risk to breastfed infants after removal of the patch from the mother's skin
Drug Levels
Phosphorus P 32 decays by beta emission with an energy of 1.709 MeV and a half-life of 14.3 days.[1]
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Mountford PJ, Wells CP, Hall FM, et al. Potential radiation dose to a breast-fed infant following administration of sodium 32P-phosphate to the mother. Nucl Med Commun. 1984;5:473–6. [PubMed: 6531156]
Substance Identification
Substance Name
Phosphorus P 32
CAS Registry Number
14596-37-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Mother-infant skin-to-skin contact after delivery results in early recognition of own mother's milk odour.[Acta Paediatr. 2004]Mother-infant skin-to-skin contact after delivery results in early recognition of own mother's milk odour.Mizuno K, Mizuno N, Shinohara T, Noda M. Acta Paediatr. 2004 Dec; 93(12):1640-5.
- Review Sodium Phosphate P 32[Drugs and Lactation Database (...]Review Sodium Phosphate P 32. Drugs and Lactation Database (LactMed). 2006
- Review Nutrition, growth, and allergic diseases among very preterm infants after hospital discharge.[Dan Med J. 2013]Review Nutrition, growth, and allergic diseases among very preterm infants after hospital discharge.Zachariassen G. Dan Med J. 2013 Feb; 60(2):B4588.
- Early skin contact combined with mother's breastfeeding to shorten the process of premature infants ≤ 30 weeks of gestation to achieve full oral feeding: the study protocol of a randomized controlled trial.[Trials. 2021]Early skin contact combined with mother's breastfeeding to shorten the process of premature infants ≤ 30 weeks of gestation to achieve full oral feeding: the study protocol of a randomized controlled trial.Li L, Wang L, Niu C, Liu C, Lv T, Ji F, Yu L, Yan W, Dou YL, Wang Y, et al. Trials. 2021 Sep 17; 22(1):637. Epub 2021 Sep 17.
- Growth and body composition of preterm infants: influence of nutrient fortification of mother's milk in hospital and breastfeeding post-hospital discharge.[Acta Paediatr. 1998]Growth and body composition of preterm infants: influence of nutrient fortification of mother's milk in hospital and breastfeeding post-hospital discharge.Wauben IP, Atkinson SA, Shah JK, Paes B. Acta Paediatr. 1998 Jul; 87(7):780-5.
- Phosphorus P 32 - Drugs and Lactation Database (LactMed)Phosphorus P 32 - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...